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Abstract 19 
Circadian abnormalities seen in Huntington’s disease (HD) patients are recapitulated in several 20 
HD transgenic mouse models. In mice, alongside the master clock located in the suprachiasmatic 21 
nucleus (SCN), two other oscillators coordinate circadian behaviour. These are the food-22 
entrainable oscillator (FEO) and the methamphetamine-sensitive circadian oscillator (MASCO). 23 
SCN- and MASCO- (but not FEO-) driven rhythms are progressively disrupted in the R6/2 24 
mouse model of HD. MASCO-driven rhythms are induced by chronic treatment with low dose of 25 
methamphetamine and characterised by an increase in period length to greater than 24 hours. 26 
Interestingly, the rhythms mediated by MASCO deteriorate earlier than those mediated by the 27 
SCN in R6/2 mice. Here, we used a pharmacological strategy to investigate the mechanisms 28 
underlying MASCO-driven rhythms in WT mice. In contrast to methamphetamine, chronic 29 
cocaine was ineffective in generating a MASCO-like component of activity although it markedly 30 
increased locomotion. Furthermore, neither blocking dopamine (DA) receptors (with the DA 31 
antagonist haloperidol) nor blocking neurotransmission by inhibiting the activity of vesicular 32 
monoamine transporter (with reserpine) prevented the expression of the MASCO-driven 33 
rhythms, although both treatments downregulated locomotor activity. Interestingly, chronic 34 
treatment with paroxetine, a serotonin specific reuptake inhibitor commonly used as 35 
antidepressant in HD, was able to restore the expression of MASCO-driven rhythms in R6/2 36 
mice. Thus, MASCO-driven rhythms appear to be mediated by both serotoninergic and 37 
dopaminergic systems. This supports the idea that abnormalities in MASCO output may 38 
contribute to both the HD circadian and psychiatric phenotype.  39 
Keywords: cognition, sleep, depression  40 
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(-)-Cocaine hydrochloride (PubChem CID: 656832); (+)-methamphetamine hydrochloride 42 
(PubChem CID: 66124); haloperidol (PubChem CID: 3559); reserpine (PubChem CID: 5770); 43 
paroxetine hydrochloride hemihydrate (PubChem CID: 62878). 44 
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Highlights (maximum 85 characters, including spaces, per bullet point) 46 
 Chronic treatment with cocaine does not induce MASCO-like rhythms in WT mice 47 
 Non-selective blockade of dopaminergic receptors does not prevent expression of MASCO 48 
in WT mice. 49 
 Treatment with the serotonin-specific reuptake inhibitor paroxetine rescues the expression of 50 
the MASCO-driven rhythms in R6/2 mice. 51 
 Serotonin is involved in the expression of MASCO-driven rhythms. 52 
 Deficit in central serotonin may contribute to circadian rhythm dysfunction in HD mice. 53 
 54 
  55 
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1. Introduction  56 
Circadian abnormalities have been described in Huntington’s disease (HD) patients, as well as in 57 
rodent and sheep models of HD (Arnulf et al., 2008; Fisher et al., 2013; Loh et al., 2013; Morton, 58 
2013; Morton et al., 2005; Piano et al., 2015). Circadian rhythms are controlled by the 59 
suprachiasmatic nucleus (SCN) that is located in the anterior hypothalamus. Under specific 60 
circumstances, two other circadian oscillators are able to generate robust behavioural rhythm 61 
independent of the SCN in rodents. These are the food-entrainable oscillator (FEO; Mistlberger, 62 
1994) and the methamphetamine (MAP)-sensitive circadian oscillator (MASCO; Honma et al., 63 
1986; Honma and Honma, 1986). The FEO in the transgenic R6/2 mouse model of HD appears 64 
to operate normally. Both the R6/2 and the full-length knock-in Q175 mice models of HD, 65 
however, show a progressive disruption in the SCN-driven rest-activity rhythms that is also seen 66 
in HD patients (Fisher et al., 2016, 2013; Loh et al., 2013; Morton et al., 2005; Ouk et al., 2016). 67 
MASCO is severely disrupted in both of these lines of mice (Cuesta et al., 2012; Ouk et al., 68 
2016), with MASCO disruption occurring long before the SCN-mediated disintegration of 69 
circadian rhythms was observed. In the R6/2 line, the expression of MASCO-driven rhythms is 70 
disrupted in > 95% of the mice by 7.5 weeks of age (Cuesta et al., 2012), many weeks before 71 
motor symptoms are seen. 72 
MASCO is induced by chronic MAP treatment at low doses and restores rhythmicity in 73 
mice rendered arrhythmic via SCN lesion (Honma et al., 1986, 1987). In SCN-intact WT mice 74 
placed in constant darkness (DD), rest-activity rhythms driven by MAP treatment are 75 
characterised by a period length that is greater than 24 hrs, and can increase up to the circabidian 76 
(48 hrs period) range. Under the influence of MAP, a distinct second component of general 77 
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activity progressively dissociate from the SCN-driven rhythms, leading to the emergence of 78 
MASCO-driven rhythms (Honma et al., 1986; Honma and Honma, 1986; for other references see 79 
Cuesta et al., 2012). The mechanisms underlying the expression of the MASCO-driven rhythms 80 
are currently unknown. 81 
The deficit of MASCO-driven rhythms in HD mice raises many questions, not only about 82 
the function of the MASCO, but also about the mechanisms underlying the MASCO. We found 83 
previously that chronic treatment with L-DOPA delayed the disruption of MASCO-driven 84 
rhythms in R6/2 mice (Cuesta et al., 2012), suggesting an early abnormality of the dopamine 85 
(DA) and/or noradrenaline (NA) systems in HD mice. A key role of DA in the expression of 86 
MASCO-driven rhythms is consistent with both the pharmacological action of MAP and the 87 
involvement of striatal dopaminergic rhythms that might act as ultradian oscillators able to 88 
generate rhythms greater than 24 hrs when dopaminergic tone is elevated (Blum et al., 2014). 89 
Consistent with this, deficits in both dopaminergic and noradrenergic systems are well described 90 
in both patients and HD mice. HD patients, at both early and late stage of the disease, exhibit a 91 
disruption in DA signaling, with reduced striatal DA levels and DA receptors (Antonini et al., 92 
1996; Ginovart et al., 1997; Sedvall et al., 1994; Weeks et al., 1996). In R6/2 mice, loss of D1 93 
receptors mRNA is evident as early as 4 weeks of age (Cha et al., 1998), with the DA system 94 
being functionally impaired and DA release severely compromised by 6 weeks of age (Hickey et 95 
al., 2002; Johnson et al., 2006). Noradrenergic receptors β1 are reported to be dramatically 96 
reduced in the basal ganglia of HD patients at late stage of disease (Waeber et al., 1991). In R6/2 97 
mice, NA neurotransmission is already decreased by 4 weeks of age in the hippocampus 98 
(Reynolds et al., 1999). Interestingly, it has been shown that MAP also affected the serotonergic 99 
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system in neurotransmitter release (Ago et al., 2008) which is disrupted in both HD patients 100 
(Steward et al., 1993) and R6/2 mice (Mochel et al., 2011; Yohrling et al., 2003). Thus, it seems 101 
possible that the major disruption of MASCO-driven rhythms in R6/2 mice is caused by early 102 
abnormalities in one or both of these biogenic amine systems. 103 
Here we conducted a pharmacological study using mice to examine some of the 104 
mechanisms that might underlie the deficits in the expression of MASCO-driven rhythms in 105 
R6/2 mice. We tested four drugs that modulate dopaminergic/noradrenergic or serotoninergic 106 
neurotransmission. First, we tested whether a chronic treatment with another dopaminergic 107 
stimulant (cocaine) than MAP could induce the expression of MASCO-driven rhythms in WT 108 
mice. We then investigated whether blocking the neurotransmission of DA/NA (using the non-109 
selective dopaminergic receptor antagonist haloperidol or the monoamine depleting agent 110 
reserpine) was sufficient to suppress the MASCO-driven rhythms in WT mice. Finally, we 111 
investigated whether chronic treatment with paroxetine (that inhibits the neuronal reuptake of 112 
serotonin (5-HT) by blocking the 5-HT transporter; SERT) had an ameliorating effect on the 113 
abnormal MASCO-driven rhythms in R6/2 mice. 114 
 115 
2. Material and methods 116 
2.1. Animals and housing conditions 117 
All of the experimental procedures were conducted in accordance with the guidelines of the UK 118 
Animals (Scientific Procedures) Act 1986 and with the approval of the University of Cambridge 119 
Animal Welfare and Ethical Review Board. 120 
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R6/2 and WT littermate mice were obtained from a colony established in the University of 121 
Cambridge (CBA x C57BL/6J background) following the breeding strategy described by 122 
Mangiarini et al. (1996). Genotyping and determination of the CAG repeat lengths were 123 
performed by Laragen (Los Angeles, CA, USA) as previously described (Morton et al., 2009). 124 
Mice were group-housed and placed under a 12 h light (~300 lux): 12 h dark cycle before the 125 
start of the experiment and had ad libitum access to food and water. Experiments were conducted 126 
in DD. For analysis of individual behavioural rhythms during the drug treatments, mice were 127 
then singly housed in a ventilated sound-proof and light-tight cabinet (Scantainer, Scanbur, 128 
Denmark). Humidity and temperature were maintained at mean (± SEM) of 55% ± 10 and 22°C 129 
± 1, respectively.  130 
We routinely use both male and female mice in our studies. While there are some sex 131 
differences (Skillings and Morton, 2016; Wood et al., 2010), using both sexes strengthens the 132 
validity of any major differences that are seen due to the HD genotype. A total of 44 WT mice 133 
(31 male and 13 female) and 36 R6/2 mice (18 male and 18 female) were distributed between 134 
four pharmacological experiments (for details of numbers and treatments see Table 1). We used 135 
an R6/2 mouse line with a CAG repeat of 250. This is a well-described R6/2 line with 136 
reproducible phenotype that exhibits many changes that recapitulate those seen in humans (brain 137 
atrophy, aggregates of mutant huntingtin and behavioral abnormalities (Lione et al., 1999; 138 
Morton et al., 2000). The behavioral phenotype and end stage brain pathology of the R6/2 250 139 
and R6/2 110 (the two line available from Jackson Laboratories) are very similar (Morton et al., 140 
2009). We use the 250 CAG repeat mouse rather than the R6/2 110 line because the development 141 
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of its phenotype takes a slower trajectory, and thus gives a wider experimental window of 142 
opportunity. The R6/2 mice used in this study had a mean ± SEM CAG repeat length of 257 ± 1.  143 
 144 
2.2. Drugs 145 
(-)-Cocaine hydrochloride (C5776), (+)-methamphetamine hydrochloride (M8750), 146 
haloperidol (H1512), reserpine (R0875) and paroxetine hydrochloride hemihydrate (P9623) have 147 
been purchased from Sigma Aldrich (UK). Cocaine was dissolved in 0.9% saline and 148 
administered to the mice with mini-osmotic minipumps (Alzet, model 1004). Haloperidol was 149 
dissolved in either polyethylene glycol vehicle (molecular weight 400 daltons) vehicle (40% 150 
PEG 400 in 0.9% saline or 5% ethanol in 0.9% saline). Reserpine was dissolved in 0.9% saline 151 
and 0.5% acetic acid. Paroxetine was dissolved in 0.9% saline at 60°C with a sonicator and left 152 
to cool to ambient temperature before administration. 153 
 154 
2.3. Drug treatment 155 
Mice were placed under DD at least a week before the start of the drug treatments. 156 
In the cocaine experiment, mini-osmotic pumps containing either 0.9% saline or cocaine 157 
hydrochloride dissolved in 0.9% saline were implanted subcutaneously into 12-week-old drug-158 
naïve WT mice under general anaesthesia (0.5-2% isoflurane). These pumps allowed chronic 159 
drug infusion for 4 weeks with a dose rate of 30 mg/kg/day. The dose of cocaine tested was 160 
chosen based on the literature (Jiang et al., 2013; Li et al., 2005) and pilot experiments (data not 161 
shown). 162 
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For haloperidol, reserpine and paroxetine experiments, the mice were given intraperitoneal 163 
injections of drugs in a volume of 100 µl per 10 g of body weight, at random times of day 164 
between 7am and 7pm to avoid any entrainment to the injections. The doses of the drugs tested 165 
were chosen based on the literature (de Jong et al., 2005; Duan et al., 2004; Fukushiro et al., 166 
2008; Maxwell et al., 2004; O’Leary et al., 2007; Roscoe et al., 2005; Skalisz et al., 2002). 167 
In the haloperidol experiment, drug-naive WT mice first received ad libitum water (7-7.5 168 
weeks) to drink for the single housing habituation period in the circadian cabinet. After this, mice 169 
were split into four groups. WT mice were given to drink either water alone or 0.005% MAP 170 
diluted in water (from 8 to 16 weeks of age). In addition, each mouse received either a saline 171 
(control) or haloperidol injections daily (from 10 to 14 weeks of age) with doses gradually 172 
increased from 0.1 mg/kg to 0.3 mg/kg and 0.5 mg/kg. Mice were distributed between 4 173 
combinations of injection and drink: saline/water (n = 5; 2 male and 3 female), saline/MAP (n = 174 
5; 3 male and 2 female), haloperidol/water (n = 11; 6 male and 5 female) and haloperidol/MAP 175 
(n = 7; 4 male and 3 female). 176 
In the reserpine experiment, we used the WT mice that had previously received 177 
haloperidol. After a wash-out period of 3 weeks during which haloperidol was withdrawn but 178 
mice continued to be given MAP, mice previously treated with haloperidol were treated with 179 
reserpine (1 mg/kg) associated with either water or MAP from 17 to 22.5 weeks of age. 180 
Reserpine or saline was administered intraperitoneally daily for the first 5 days, then every 3 181 
days thereafter. 182 
For the paroxetine experiment, drug-naïve R6/2 mice were treated daily between 6 and 12 183 
weeks of age with either vehicle or paroxetine at a dose of 20 mg/kg. WT mice have normal 184 
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levels of 5-HT and express robust MASCO-driven rhythms. Since the purpose of the experiment 185 
was to see if paroxetine treatment could restore the MASCO-driven rhythms, and there is a 186 
significant risk for 5-HT syndrome in WT mice after SSRI treatment (Haberzettl et al., 2013; 187 
Kalueff et al., 2008; AJM unpublished data), we did not treat WT mice with chronic paroxetine. 188 
R6/2 mice were examined daily to detect any sign of Straub tail (S-shaped dorsiflexion), a 189 
typical sign of 5-HT syndrome. None of the R6/2 mice developed this sign during the study. 190 
Concomitantly with paroxetine or vehicle injections, mice were given either water alone or 191 
0.005% MAP diluted in water (from 8 to 12 weeks). Mice were distributed into one of 4 groups 192 
that received different combination of drug injections and water only or 0.005% MAP diluted in 193 
water to drink. Those were: saline/water (n = 6; 3 male, 3 female), saline/MAP (n = 6; 3 male, 3 194 
female), paroxetine/water (n = 12; 6 male, 6 female) and paroxetine/MAP (n =12; 6 male and 6 195 
female). Note that for the groups treated with paroxetine, the drug treatment was started two 196 
weeks before MAP was administered, as while the action of antidepressants on the transporter is 197 
rapid and acutely inhibits neurotransmitters reuptake (Hirano et al., 2005), improvements of 198 
behavioural disturbances are delayed and observed only after weeks of repeated treatment 199 
(Hébert et al., 2001; Montgomery, 1997). 200 
 201 
2.4. Circadian analysis 202 
General activity was recorded continuously from individually housed mice in the circadian 203 
cabinet with infrared movement sensors (Bosch, Germany) placed on top of each cage and linked 204 
to a computerised recording system (Clocklab; Actimetrics, Wilmette, IL, USA). 205 
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Double plotted actograms in 5-min block size were generated with Clocklab software, for 206 
analysis of the circadian parameters of the locomotor rhythms. Period lengths were determined 207 
by fitting a least-square regression line to the activity onsets of the data periods analysed. 208 
Duration of active period was calculated as the difference between the means of the regression 209 
lines drawn through the 7 or 14 activity onsets and corresponding offsets. Lomb-Scargle 210 
periodograms were used to determine behavioural rhythmicity using a line of significance at 211 
0.001. Only rhythmic mice were included in the analysis of period length and duration of active 212 
period. General activity during active and rest period was determined using the profile activity 213 
function of the Clocklab software. 214 
 215 
2.5. Statistical analysis 216 
Statistical analyses were performed using Statistica software (version 13.2, StatSoft Inc., Tulsa, 217 
USA). Analysis of variance (ANOVA) with repeated measures was performed to investigate 218 
differences between groups. When main or interactions effects were identified, a Bonferroni 219 
post-hoc test was used to determine significant effects with P < 0.05. 220 
 221 
3. Results 222 
3.1. Methamphetamine, but not cocaine, induced the expression of MASCO-driven 223 
rhythms in WT mice 224 
In WT mice placed under DD and given water alone to drink, a typical free-running circadian 225 
locomotor activity rhythm was observed with a period length between 23 and 24 hrs (Figs. 1A 226 
and D). When mice were treated with 0.005% MAP in the drinking water, all WT mice 227 
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expressed two distinct components of the general activity rhythms, as previously described 228 
(Cuesta et al., 2012; Fig. 1B). These were the SCN component, with a period length of ~24 hrs 229 
and the MASCO component, with period lengths > 24 hrs (Fig 1B, C). 230 
When WT mice were treated with cocaine, we did not observe the emergence of the second 231 
component of activity that is typically seen with MAP treatment (Fig.1E and F). Nevertheless, 232 
the cocaine was pharmacologically effective, since at the beginning of cocaine treatment, there 233 
was a pronounced, but transient, increase in general activity that lasted around 48 hrs during 234 
which mice were constantly hyperactive. After this hyperactive period, all mice treated with 235 
cocaine returned to a ~24 hrs rest-activity rhythm pattern. We did not find any main effect of 236 
cocaine treatment on period length (that remained ~24 hrs), active period duration or rest/activity 237 
ratio (Table 2 and supplementary Fig. 1). There was a main effect (increase with increased 238 
time) of treatment duration on activity counts [F (5,70) = 3.89; P < 0.01but post-hoc test did not 239 
reveal any significant difference between control mice and cocaine-treated mice at any of the 240 
individual weeks analysed. 241 
 242 
3.2.  Haloperidol and reserpine reduce locomotor activity but MASCO-driven rhythms 243 
can still be invoked in WT mice 244 
We found an interaction effect of haloperidol and dose on activity counts in the active period [F 245 
(7,168) = 2.75; P < 0.01]. Haloperidol significantly reduced the general activity of mice drinking 246 
water (Fig. 2C, Fig. 3A) compared to the week before the treatment (P < 0.001) and compared to 247 
washout week (P < 0.001). This reduction of general activity was reversible, with the level of 248 
general activity returning to normal within ~6 days of stopping the drug treatment (Fig. 2C; P < 249 
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0.001). After ~2 weeks of treatment, haloperidol suppressed activity onset of the SCN 250 
component, although activity offset could still be observed (Fig. 2C and D). Period length in DD 251 
during haloperidol treatment remained stable with < 24hrs (Fig. 2C and D), similar to mice 252 
treated with vehicle (Fig. 2A and B).  253 
The general rest-activity patterns of mice in the saline/MAP group (Fig. 2E and F) was as 254 
expected, with the clear emergence of a MASCO-driven rhythm component within ~2 weeks. In 255 
the haloperidol/MAP group, however, while there was a significant reduction in the general 256 
activity of the mice (Figs. 2G and 3B) compared to the week before haloperidol treatment 257 
started and the washout week (P < 0.01); the mice still expressed MASCO-like rhythms (Figs. 2, 258 
H and 3G). There was a main effect of haloperidol on the amplitude of both SCN- and MASCO-259 
driven rhythms, which was decreased by the drug but this was not confirmed by post hoc 260 
analyses (Figure 3F). In 6 out of 7 mice, the period length of the MASCO-driven rhythms ranged 261 
between 24.01 and 32.56 hrs. One out of seven of the mice expressed circabidian (48 hrs) 262 
MASCO-driven rhythms. 263 
After a ‘washout’ period of 3 weeks, we treated the mice with reserpine to study the effect 264 
of the depletion of catecholamines on the circadian rhythms and the expression of the MASCO-265 
driven rhythms. We found a main effect of reserpine on the activity during the active period of 266 
WT mice [F (3,23) = 7.28; P < 0.01]. This was significantly reduced in reserpine-treated mice 267 
drinking water only (Fig. 3C, Fig. 4C) during their treatment, compared to the week before the 268 
treatment started (P < 0.001) or to the mice treated with vehicle (Fig. 4A). Period length during 269 
reserpine treatment was with a period length of ~24h, similar to that of mice treated with vehicle 270 
(Fig. 4B-D). In the reserpine/MAP group, while reserpine progressively reduced the general 271 
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activity of the mice (Fig. 3D, Fig. 4G), they still expressed robust MAP-driven rhythms that 272 
ranged between 24.27 and 49.51 h (Fig. 3H, Fig. 4G, H) as their amplitude was not significantly 273 
affected (Fig. 3H), with three out of seven of the mice expressing circabidian rhythms. Our 274 
results show that lowering DA or blocking DA receptors induced a pronounced downregulation 275 
of locomotor activity but did not suppress the induction of the MASCO-driven rhythms. 276 
 277 
3.3. Paroxetine delays disruption of MASCO-like rhythms in R6/2 mice 278 
Since haloperidol and reserpine could inhibit activity but not suppress the MASCO-driven 279 
rhythms in WT mice, we considered the possible involvement of the serotonergic system in the 280 
MASCO abnormalities in R6/2 mice. To investigate this, we pre-treated R6/2 mice chronically 281 
with paroxetine, a selective 5-HT reuptake inhibitor (SSRI). Paroxetine modulated the general 282 
activity patterns in R6/2 mice. In the R6/2 paroxetine/water group, there was a change in general 283 
activity that was manifest as a fragmentation of the rest-activity patterns (Fig. 5C) compared to 284 
R6/2 saline/water group (Fig. 5A). Only a single component (SCN-driven) of general activity 285 
was observed in these groups (Fig. 5B and D). There was no main effect of drug treatment on 286 
period length [F (1,75) = 0.40; P > 0.05; Table 3 and Fig. 6A and B] or rest-activity ratio [F (1,80) = 287 
0.27; P > 0.05; Table 4 and Fig. 7C]. There was however a main effect of drug treatment on 288 
duration of active period in water-drinking mice [F (1,16) = 6.92; P < 0.05; Fig 7A] although post-289 
hoc tests did not reveal specific timepoints at which the shortening was significant (with 290 
maximal shortening at week 4; 13.43 ± 0.21 vs. 14.79 ± 0.44). There was also a main effect of 291 
drug treatment on the general activity during active period [F (1,16) = 14.65; P < 0.01] with 292 
activity counts significantly decreased in paroxetine-treated R6/2 mice compared to saline-293 
15 
 
treated mice at week 3 (P < 0.05) and week 6 (P < 0.01) of drug treatment (Table 4 and Fig. 294 
7E).  295 
R6/2 mice from the saline/MAP group exhibited an increase of total activity in the active 296 
period, with a significant main effect of treatment duration on rest-activity rhythms [F (5,75) = 297 
0.17; P < 0.001; Table 4 and Fig. 7F]. The mice expressed, however, only the SCN component 298 
of the general activity, and did not show the MASCO-like rhythms (Fig. 5E and F; Fig. 6C). 299 
This is consistent with our previous study (Cuesta et al., 2012). Analysis of period length of the 300 
SCN component revealed no differences between R6/2 mice given water and those given water 301 
containing MAP (Table 3). Interestingly, seven out of twelve R6/2 mice given MAP and treated 302 
concomitantly with paroxetine developed MASCO-like rhythms (See an example in Fig. 5G and 303 
H; Fig. 6D), from week 3 to week 4 of MAP treatment when the mice were 10-11 weeks of age. 304 
During this time the period length of the MASCO component ranged from 24.04 to 32.06 h. We 305 
also found main effects of paroxetine treatment and treatment duration on SCN period length in 306 
R6/2 mice drinking methamphetamine [F (1,15) = 8.50; P < 0.05 and F (5,75) = 5.10; P < 0.001], 307 
although post hoc analysis did not reveal any significant differences between paroxetine- and 308 
saline-treated mice week per week (Table 3). We did not, however, find any effect of paroxetine 309 
treatment on the general activity counts (either during rest or active period), rest-activity ratio or 310 
duration of active period (Table 4 and Fig. 7B, D and F) in mice drinking methamphetamine. 311 
 312 
4. Discussion 313 
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MASCO-driven rhythms are widely believed to be mediated via central dopaminergic 314 
mechanisms (Blum et al., 2014; Cuesta et al., 2012). Blocking DA neurotransmission, however, 315 
was not sufficient to suppress the MASCO-driven rhythms in WT mice as they were still 316 
observed when MAP consumption was combined with chronic treatment of either haloperidol or 317 
reserpine. Although 5-HT has not previously been implicated in the mechanisms underlying the 318 
MASCO-driven rhythms, we found that in R6/2 mice carrying 250 CAG repeats (that normally 319 
do not express them) MASCO-like rhythms could be induced in animals pretreated with 320 
paroxetine. Together, our results suggest that abnormalities in the serotoninergic system, in 321 
addition to deficits in the dopaminergic/noradrenergic systems, underlie the disruption of the 322 
MASCO-driven rhythms in the R6/2 mouse. 323 
MAP acts primarily on dopaminergic neurons to increase extracellular DA levels. Thus, an 324 
intact dopaminergic system is likely to be necessary for the normal generation of the MASCO-325 
driven rhythms while a deficit associated with abnormal expression of DA may disrupt their 326 
manifestation. Consistent with this, L-DOPA was able to partially restore the expression of 327 
MASCO-driven rhythms in R6/2 mice carrying 250 CAG repeats (Cuesta et al., 2012). 328 
Abnormalities in the dopaminergic system in HD are well-documented in both patients (Andrews 329 
et al., 1999; Antonini et al., 1996; Bäckman et al., 1997; Bäckman and Farde, 2001; Bernheimer 330 
et al., 1973; Chen et al., 2013; Ginovart et al., 1997; Guo et al., 2012; Kish et al., 1987) and 331 
animal models (Chen et al., 2013; Hickey et al., 2002; Squitieri et al., 2015; Tyebji et al., 2015). 332 
It seems likely that some of the changes in circadian behaviour in HD mice, and by extrapolation 333 
in HD patients, are partially caused by abnormalities in the DA system. For ethical reasons, the 334 
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existence of the MASCO in humans has not yet been investigated. Therefore, the importance of 335 
its possible dysfunction in HD must remain a matter for speculation. 336 
There is considerable evidence, both direct and indirect, for a role of DA in both HD and in 337 
modulation of circadian rhythms. An important body of evidence has emerged recently showing 338 
that the elevation of striatal DA signalling lengthens the circadian period (Blum et al., 2014; 339 
Landgraf et al., 2016). It has been shown previously that clock genes are involved in the 340 
regulation of striatal DA activity (Hampp et al., 2008; McClung et al., 2005; Roybal et al., 2007) 341 
and are down-regulated in HD mice (Morton et al., 2005). Furthermore, dopaminergic receptor 342 
agonists influence neuronal clock gene expression (Imbesi et al., 2009). The rhythm of 343 
expression of striatal PER2 depends on daily dopaminergic activation of D2 receptors (Hood et 344 
al., 2010) and the activation of D2 receptor signalling enhances the circadian regulation by 345 
CLOCK and BMAL1 (Yujnovsky et al., 2006).  346 
Methamphetamine and cocaine both increase levels of DA in synapses (Sofuoglu and 347 
Sewell, 2009) but chronic treatment with cocaine in WT mice did not induce the expression of a 348 
second component of general activity as is seen after chronic MAP treatment. Due to the 349 
relatively short half-life of cocaine and its poor solubility, we did not attempt to deliver cocaine 350 
via drinking water, as this would have required the mice to drink constantly to maintain high 351 
enough cocaine levels in the brain to release DA at similar levels to MAP. Instead, we used an 352 
osmotic minipump to deliver cocaine chronically. While we did not measure plasma levels of 353 
cocaine, we are confident that the cocaine was released from the minipumps, since we saw a 354 
clear increase in activity in response to cocaine at onset of drug treatment. In fact, the animals 355 
were hyperactive and moved constantly for the first two days after minipump implantation. This 356 
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is likely to correspond to the period of sensitisation/intensification of behavioural stereotypy 357 
induced by cocaine described in the literature (Johansson et al., 1992). Thereafter, the cocaine-358 
treated mice habituated to the drug and resumed a circadian cycle, albeit with a different period 359 
and a more fragmented locomotor activity (Fig. 1E and F). It has been shown that the route of 360 
cocaine administration influenced the drug effects (King et al., 1992). An attenuation of 361 
behavioural response upon chronic administration of cocaine has been described, with 362 
continuous infusion of cocaine via Alzet minipumps, but not with daily cocaine intraperitoneal 363 
injection, producing tolerance (Reith et al., 1987). This tolerance to cocaine appears to be a 364 
robust compensatory mechanism and is manifest for at least 7 days after the cocaine treatment is 365 
stopped (King et al., 1992). 366 
The mechanisms of action of cocaine and MAP are different (for review, see; Chiu and 367 
Schenk, 2012). Cocaine increases DA levels in the presynaptic cleft by blocking the DAT and 368 
preventing DA reuptake back in the neuron. By contrast, MAP not only competes with DA at the 369 
DAT to prevent its reuptake but is also transported into the presynaptic terminal by DAT. Once 370 
in the cytosol, MAP is transported into the vesicles where it induces the release of 371 
neurotransmitter. MAP also slows the inactivation of DA and NA by inhibiting monoamine 372 
oxidase (Egashira and Yamanaka, 1993). Moreover, a study reporting the effects of MAP and 373 
cocaine on inhibitory postsynaptic current mediated by D2 autoreceptors (Branch and Beckstead, 374 
2012) suggested that the two drugs exerted differential kinetics in intracellular actions for 375 
dopamine transmission. Therefore, the expression of MASCO-driven rhythms may be rendered 376 
possible by complex pharmacokinetic and dynamic actions of MAP rather than to a single 377 
increase in DA in the synapse cleft. Furthermore, it seems that MAP also influence the circadian 378 
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circadian via the expression of clock genes. The induction of MASCO-driven rhythms does not 379 
require the full repertoire of the clock genes (Mohawk et al., 2009). Nevertheless, since 380 
MASCO-driven rhythms were observed in lines of mice with single or double mutations in 381 
principal clock genes (Per1/Per2, Cry1/Cry2, Bmal and Clock) even if they were arrhythmic 382 
(Honma et al., 2008; Masubuchi et al., 2001; Mohawk et al., 2012), it is possible that clock genes 383 
also play a role in the timing of MASCO. Interestingly, it has been reported that MAP treatment 384 
specifically induced a shift of the expression of Per 1 and Per 2 in the striatum from a nocturnal 385 
to a diurnal rhythm while their expression in the SCN was unaffected (Iijima et al., 2002). 386 
Furthermore, although Per gene knockout mice express MASCO-driven rhythms, these are 387 
atypical. For example, MASCO-driven rhythms in Per2 knock-out mice were reported to be 388 
uncoupled from SCN rhythms (Pendergast et al., 2013). MASCO-driven rhythms in a triple 389 
knockout mouse for Per1, 2 and 3 with lesioned SCN were unusually short (around 21h; 390 
Pendergast et al., 2012), while double knockout of Per1 and 2 mice exhibited MASCO rhythms 391 
that alternated between short (22h) and long period (27h; Pendergast et al., 2012). A role for Per 392 
genes in the expression of MASCO-driven rhythms is relevant in our case as both Per1 and Per2 393 
expressions are dysregulated in the striatum of R6/2 mice (Morton et al., 2005), with a truncation 394 
of the peak expression. This may explain the MASCO-driven rhythms observed in R6/2 mice 395 
treated with paroxetine with short periods of e.g. 24.04 h. Therefore, the dysregulated expression 396 
of Per genes in R6/2 mice may also contribute to the MASCO dysfunction. 397 
We found that blocking the DA/NA neurotransmission with either haloperidol or reserpine 398 
in MAP-treated WT mice reduced the level of general activity of the mice (showing that the 399 
drugs were efficacious). Neither drug, however, suppressed the MASCO-driven rhythms. This 400 
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suggests that the expression of MASCO-driven rhythms is not dependent solely on DA/NA. 401 
Although circadian rhythms were masked by both the decrease in general activity and 402 
fragmentation of the rhythms, both SCN- and MASCO-driven rhythms reappeared quickly 403 
(within 1-2 days) once the drug administration stopped. It was not possible to use a higher dose 404 
of haloperidol to treat the mice as blocking DA receptors reduced motivation to move, eat and 405 
drink (Zis and Fibiger, 1975). 406 
It has been shown that chronic MAP treatment also modulated the serotonergic system 407 
(Ago et al., 2008; Tanaka et al., 2016). A role for 5-HT in the MASCO-driven rhythms however, 408 
has not been suggested previously. It is, however interesting to consider this as an underlying 409 
cause of an HD-related abnormality in MASCO, since a decrease in 5-HT and its metabolite 5-410 
hydroxyindoleacetic acid (Mochel et al., 2011), as well as a reduction in the activity of 411 
tryptophan hydroxylase, the rate-limiting enzyme in biosynthesis of 5-HT (Yohrling et al., 2002) 412 
have been described in both patients and HD mice models. Deficits in serotoninergic 413 
transmission have been implicated in depression, a psychiatric disturbance often diagnosed in 414 
HD patients (Paulsen et al., 2005) and commonly treated with SSRIs such as paroxetine (Nevels 415 
et al., 2016). Depressive-like behaviours have been described in R6/2 mice (Ciamei et al., 2015; 416 
Pang et al., 2009). Interestingly, SSRIs have been shown to improve cognitive and affective 417 
behavioral disorder in R6/2 and other lines of HD mice (Duan et al., 2008; Peng et al., 2008). For 418 
example, fluoxetine improves hippocampal-dependent cognitive and depressive-like behavioural 419 
symptoms (Grote et al., 2005) and sertraline improved the deficits seen in the forced swim test in 420 
female R6/1 mice (Renoir et al., 2012). Furthermore, SSRIs including fluoxetine, sertraline and 421 
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paroxetine increase levels of brain-derived neurotrophic factor (BDNF; a protein necessary for 422 
neuron survival), and improved neurogenesis deficits in HD mice (Peng et al., 2008). 423 
The antidepressant action of paroxetine involves increased availability of 5-HT in the 424 
synapse and has been shown to improve 5-HT agonism on 5-HT2A receptors in the cortex of 425 
young patients with depression after 6 weeks of treatment (Meyer et al., 2001). R6/2 250 CAG 426 
repeat mice develop sleep abnormalities such as increase of REM sleep during the dark period, 427 
slowing down of REM sleep theta rhythms and abnormal low gamma oscillations seen in sleep 428 
electroencephalography (EEG; Kantor et al., 2013). We have shown recently that chronic, but 429 
not acute, treatment of R6/2 250 CAG repeat mice with paroxetine was able to prevent 430 
electroencephalographic abnormalities in R6/2 mice if treatment started before symptom onset. 431 
This suggests that correcting abnormalities in the 5-HT system stabilized cortical circuits in R6/2 432 
mice (Kantor et al., 2017). Here we found that when chronic paroxetine was started at a 433 
presymptomatic age, it allowed MASCO-driven rhythms to be induced at a time when they are 434 
not normally inducible in R6/2 mice. Together these data suggest that normal cortical function 435 
may be necessary for the development of MASCO-driven rhythms.  436 
The most parsimonious interpretation of our data is that both 5-HT and DA are important 437 
for the expression of MASCO-driven rhythms. In future studies this should be explored further. 438 
For example, dopaminergic neurons in the mid striatum have been shown to directly influence 439 
the MAP-driven rhythms as silencing them with the DDREADs technique suppressed the 440 
rhythms (Blum et al., 2014). It would be very interesting to take a similarly direct approach to 441 
determining the role of the serotonergic neurons of the Raphe nucleus in the generation of the 442 
MASCO-driven rhythms. The interactions between dopaminergic and serotonergic systems are 443 
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complex. For example, several lines of evidence show that chronic paroxetine not only acts on 444 
serotoninergic neurotransmission by downregulating SERT (Hirano et al., 2005), but also exerts 445 
a modulation on the dopaminergic and the noradrenergic receptor systems (Nakayama, 2002; 446 
Redrobe et al., 1998). Depressed patients treated with paroxetine exhibited elevated DAT 447 
binding (Kugaya et al., 2003). Furthermore, local action of SSRIs in the nucleus accumbens 448 
(NAc) mediates a DA efflux from that structure (Parsons and Justice, 1993), resulting in the 449 
enhancement of cocaine-evoked hyperactivity (Bubar et al., 2003). Other studies showed that the 450 
5-HT3 antagonist ganisetron inhibited the paroxetine-induced increase in extracellular DA levels, 451 
but did not change 5-HT levels in rat medial prefrontal cortex (Nakayama, 2002) or olfactory 452 
bulb slices (Zazpe et al., 1994). This suggests that paroxetine could increase DA levels via the 453 
stimulation of 5-HT3 receptors present on dopaminergic neurons. Interestingly, modulatory 454 
effects of paroxetine on NA system have also been reported. In patients with major depression 455 
treated with paroxetine, NA uptake was inhibited (Gilmor et al., 2002). Moreover, paroxetine 456 
inhibits the neuronal uptake of NA, as well as 5-HT (Redrobe et al., 1998). The ability of 457 
paroxetine to restore the MAP-driven rhythms in R6/2 mice when the treatment started at 458 
presymptomatic age, similar to what we had shown previously with L-DOPA (Cuesta et al., 459 
2012), may be due not only to its ability to increase the levels of 5-HT, but to indirect 460 
modulatory effects on DA and NA neurotransmission.  461 
Beneficial effects of paroxetine have been observed in a number of animal models of 462 
neurodegenerative diseases. For example in a mouse model of Parkinson’s disease, treatment 463 
with paroxetine prevented degeneration of nigrostriatal dopaminergic neurons, increased striatal 464 
DA levels and improved motor function (Chung et al., 2010). Paroxetine delayed neuronal 465 
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degeneration and motor dysfunction, increased brain-derived neurotropic factor and improved 466 
energy metabolism, insulin sensitivity and the survival in the HD-N171-82Q mouse model of 467 
HD (Duan et al., 2004) that express the human N-terminal truncated huntingtin with 82 468 
polyglutamine repeats driven by a mouse prion protein promoter (Duan et al., 2004). Effects of 469 
paroxetine on circadian rhythms have not been described in mouse models of other neurological 470 
diseases. This would be worth studying further. 471 
In conclusion, we have shown that abnormalities in MASCO in R6/2 mice can be 472 
ameliorated with chronic paroxetine treatment. Our findings suggest that, in addition to the 473 
dopaminergic/noradrenergic systems dysfunction previously described, an early abnormality in 474 
the serotoninergic system may contribute to the impairment of the MASCO observed in the R6/2 475 
mouse. Given the propensity for depression in HD patients, deficits in 5-HT may also be 476 
involved in the circadian abnormalities and resulting behavioural disturbances observed in HD 477 
patients. 478 
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Legend to figures 803 
 804 
Figure 1. Methamphetamine but not cocaine induces a second component of general 805 
activity with period length > 24 hours in WT mice 806 
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Double-plotted actograms (A-F) show rest-activity patterns recorded from WT mice in DD 807 
between 6 to 14 weeks (A-C) or from 10 to 19 weeks (D-F) of age. The arrows on the right of the 808 
actograms show when mice were given water (A-F; dotted line) or 0.005% methamphetamine 809 
(MAP) (B and C; solid line) via the drinking bottle. The arrows with solid line on the right of the 810 
actograms D-F show infusion of saline (D) or 30mg/kg cocaine (E and F) via osmotic minipump. 811 
The dashed red and solid blue lines within actogram B represents the period length of SCN- and 812 
MASCO-driven rhythms, respectively. Actogram B is replotted in C with the x-axis changed to 813 
the value of the period length of MASCO-driven rhythms (~ 29 h). Actogram E is replotted in F 814 
with the x-axis changed to the value of the period length of SCN-mediated rhythms (~ 23.7 h). 815 
Asterisks in D, E & F indicate day of osmotic minipump implantation. 816 
 817 
Figure 2. Haloperidol blocks diurnal activity but not the expression of the MASCO-driven 818 
rhythms in WT mice. Double-plotted actograms (A, C, E and G) show rest-activity patterns in 819 
WT mice in DD from 8 to 16 weeks. The arrow on the right of the actograms shows the period 820 
during which daily injections of saline (A and E) or haloperidol (C and G) were given. The 821 
dotted and the dashed lines on the right of the actograms indicate the period during which mice 822 
had water only (A and C) or 0.005% MAP (E and G) to drink. Periodograms (B, D, F and H) 823 
with dotted line of significance fixed at P < 0.001, were determined for the weeks (w) indicated 824 
by the black bar at the left of each corresponding actogram (A, C, E and G). 825 
 826 
Figure 3. Haloperidol and reserpine both decrease general activity but do not prevent the 827 
expression of MASCO-driven rhythms. Scatter plots show activity count during active period 828 
41 
 
(A-D), amplitude of period lengths (E and F) of the rhythms driven by SCN (open squares) or 829 
MASCO (filled squares) and values of period lengths of SCN- and MASCO-driven rhythms (G 830 
and H) for individual WT mice. Mice were given to drink water only (A and C) or 0.005% MAP 831 
(B and D), and received concomitantly either haloperidol (0.5mg/kg; A, B and E) or reserpine 832 
(0.1mg/kg; C and D, F) injections. The bars above the x-axis in E and F indicate the 833 
experimental weeks with methamphetamine either alone (white) or concomitantly given with 834 
treatment of haloperidol or reserpine (grey). *P < 0.05; **P < 0.01; ***P< 0.001. The section 835 
sign (§) in E indicates the experimental weeks for which MASCO-driven rhythms were not 836 
observed.  837 
 838 
Figure 4. Reserpine downregulates activity but does not prevent the expression of the 839 
MASCO rhythms in WT mice. Double-plotted actograms (A, C, E and G) show rest-activity 840 
patterns in WT mice in DD from 18 to 22 weeks. The arrow on the right of the actograms shows 841 
the period during which daily injections of saline (A and E) or reserpine (C and G) were given. The 842 
dotted and dashed lines on the right of the actograms indicate the period where mice were given 843 
water alone (A and C) or 0.005% MAP (E and G) to drink. Periodograms (B, D, F and H) with 844 
line of significance fixed at P < 0.001, were determined for the periods (weeks (w) 1, 5) 845 
indicated by the black bars at the left of each corresponding actogram. 846 
 847 
Figure 5. Chronic paroxetine partially restores the expression of the MASCO-driven 848 
rhythms in R6/2 mice.  849 
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Double-plotted actograms (A, C, E and G) show rest-activity patterns in R6/2 mice in DD from 6 850 
to 12 weeks. The arrow on the right of the actograms shows the period of the daily injections of 851 
saline (A and E) or paroxetine (C and G). The dotted and dashed lines on the right of the 852 
actograms indicate the duration of water alone (A and C) or 0.005% methamphetamine treatment 853 
(E and G). Periodograms (B, D, F and H) with dotted line of significance fixed at P < 0.001, 854 
were determined for the weeks (w) indicated by the black bar at the left of each corresponding 855 
actogram. 856 
 857 
Figure 6. Paroxetine prevents the disruption of the MASCO-driven rhythm expression in 858 
presymptomatic R6/2 mice. Scatter plots show period lengths of the rhythms driven by SCN or 859 
MASCO for individual WT mice treated with water only (A, B) or 0.005% MAP (C, D), 860 
concomitantly with saline (A, C) or paroxetine (20mg/kg; B, D) intraperitoneal injections. The 861 
bars above the x-axis indicates the experimental weeks during which treatment was with MAP 862 
(black) or water (white). 863 
 864 
Figure 7. Effect of paroxetine on circadian parameters. Duration of active period (A, B), rest-865 
activity ratio (C, D), activity during the active phase (E, F) and during the rest phase (G, H) are 866 
shown for paroxetine/water mice (A, C, E, G), paroxetine/MAP mice (B, D, F, H) and for the 867 
respective controls during the 6 weeks of drug treatment (between 6 and 11 weeks of age). 868 
Saline/water group is in white histograms, paroxetine/water in black histograms. Saline/MAP 869 
group is shown in grey-hatched and paroxetine/MAP group in black-hatched histograms. Data 870 
were averaged across 7 days and are presented as means ± SEM. *P < 0.05, **P < 0.01. 871 
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 872 
Supplementary Figure 1. The effect of cocaine on circadian parameters. Period length (A), 873 
duration of active period (B), general activity (C) and rest-activity ratio (D) are shown for 874 
cocaine-treated mice (black histograms) and in saline-treated mice (white histograms) before 875 
drug delivery by osmotic minipump (experimental weeks 1-2), during drug delivery (weeks 3-6) 876 
and during drug withdrawal (weeks 6-7). Data were averaged across 7 days and are presented as 877 
means ± SEM.  878 
  879 
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Table 1. Numbers of WT and R6/2 mice tested in the pharmacological studies 880 
 881 
experiment  genotype saline + water saline + MAP drug + water drug +MAP 
    males females males females males females males females 
cocaine WT 10 0 0 0 6 0 0 0 
haloperidol  WT 2 3 3 2 6 5 4 3 
reserpine WT 2 3 3 2 6 5 4 3 
paroxetine R6/2 3 3 3 3 6 6 6 6 
  882 
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Table 2. Effect of cocaine 30mg/kg on circadian parameters of WT mice 883 
treatment 
period 
treatment group period length duration of active 
period 
general activity rest/activity ratio 
    mean ± SEM (number of mice) 
pre-treatment saline 23.70 ± 0.04 (10) 13.38 ± 0.66 (10) 2800 ± 262 (10) 0.16 ± 0.03 (10) 
 
cocaine 23.55 ± 0.08 (6) 13.79 ± 0.90 (6) 2775 ± 265 (6) 0.24 ± 0.05 (6) 
week 1 saline 23.76 ± 0.07 (10) 14.10 ± 0.47 (10) 3369 ± 199 (10) 0.19 ± 0.02 (10) 
 
cocaine 23.66 ± 0.08 (6) 14.70 ± 0.72 (6) 3878 ± 572 (6) 0.30 ± 0.05 (6) 
week 2 saline 23.66 ± 0.07 (10) 14.09 ± 0.57 (10) 3757 ± 204 (10) 0.25 ± 0.05 (10) 
 
cocaine 23.61 ± 0.06 (6) 15.80 ± 0.67 (6) 3592 ± 350 (6) 0.23 ± 0.05 (6) 
week 3 saline 23.80 ± 0.13 (10) 15.09 ± 0.51 (10) 3170 ± 182 (10) 0.21 ± 0.05 (10) 
 
cocaine 23.56 ± 0.15 (6) 16.09 ± 0.82 (6) 3434 ± 268 (6) 0.27 ± 0.09 (6) 
week 4 saline 23.83 ± 0.08 (10) 14.94 ± 0.60 (10) 3035 ± 213 (10) 0.22 ± 0.08 (10) 
 
cocaine 23.65 ± 0.04 (6) 15.20 ± 0.69 (6) 3132 ± 318 (6) 0.18 ± 0.06 (6) 
washout saline 23.95 ± 0.12 (10) 14.95 ± 0.63 (10) 2737 ± 226 (10) 0.32 ± 0.08 (10) 
  cocaine 23.63 ± 0.02 (6) 15.25 ± 0.91 (6) 2891 ± 412 (6) 0.36 ± 0.12 (6) 
 884 
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Table 3. Effect of chronic methamphetamine and paroxetine 30mg/kg treatments on period 886 
length and duration of active period in R6/2 mice 887 
treatment period treatment drug period length (SCN) period length                  
(MASCO output) 
duration of active 
period 
      mean ± SEM (number of mice) 
week 1 water saline 23.61 ± 0.11 (6) none 14.03 ± 0.26 (6) 
 
water paroxetine 23.78 ± 0.07 (12) none 13.06 ± 0.38 (12) 
 
MAP saline 23.61 ± 0.09 (6) none 13.19 ± 0.70 (6) 
 
MAP paroxetine 23.96 ± 0.06 (12) none 13.44 ± 0.24 (12) 
week 2 water saline 23.64 ± 0.03 (6) none 13.92 ± 0.43 (6) 
 
water paroxetine 23.83 ± 0.03 (12) none 13.09 ± 0.33 (12) 
 
MAP saline 23.72 ± 0.08 (6) none 13.21 ± 0.74 (6) 
 
MAP paroxetine 23.74 ± 0.06 (12) none 13.00 ± 0.15 (12) 
week 3 water saline 23.62 ± 0.09 (6) none 12.65 ± 0.66 (6) 
 
water paroxetine 23.74 ± 0.05 (12) none 12.55 ± 0.24 (12) 
 
MAP saline 23.62 ± 0.10 (6) none 13.11 ± 0.74 (6) 
 
MAP paroxetine 23.80 ± 0.05 (12) 25.61 ± 0.96 (4) 13.34 ± 0.32 (12) 
week 4 water saline 23.50 ± 0.18 (6) none 14.30 ± 0.20 (6) 
 
water paroxetine 23.69 ± 0.07 (12) none 13.03 ± 0.29 (12) 
 
MAP saline 23.53 ± 0.15 (6) none 14.42 ± 0.62 (6) 
 
MAP paroxetine 23.75 ± 0.06 (12) 25.31 ± 0.62 (4) 14.37 ± 0.33 (12) 
week 5 water saline 23.57 ± 0.19 (6) none 14.79 ± 0.44 (6) 
 
water paroxetine 23.65 ± 0.08 (12) none 13.43 ± 0.21 (12) 
 
MAP saline 23.52 ± 0.16 (6) none 15.19 ± 0.98 (6) 
 
MAP paroxetine 23.76 ± 0.08 (12) 25.83 ± 0.62 (5) 15.08 ± 0.41 (12) 
week 6 water saline 23.46 ± 0.16 (6) none 14.41 ± 0.61 (6) 
 
water paroxetine 23.64 ± 0.13 (11) none 13.54 ± 0.32 (12) 
 
MAP saline 23.29 ± 0.16 (6) none 14.48 ± 1.06 (6) 
 MAP paroxetine 23.67 ± 0.06 (12) 27.74 ± 1.92 (4) 14.44 ± 0.38 (12) 
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Table 4. Effect of chronic methamphetamine and paroxetine 30mg/kg treatments on 889 
general activity in R6/2 mice 890 
treatment 
period treatment drug activity (active period) activity (rest period) rest/activity ratio 
      mean ± SEM (number of mice) 
week 1 water saline 1734 ± 329 (6) 543 ± 125 (6) 0.33 ± 0.07 (6) 
 
water paroxetine 1012 ± 68 (12) 377 ± 52 (12) 0.39 ± 0.06 (12) 
 
MAP saline 1498 ± 231 (6) 366 ± 43 (6) 0.26 ± 0.02 (6) 
 
MAP paroxetine 1047 ± 125 (12) 359 ± 43 (12) 0.39 ± 0.06 (12) 
week 2 water saline 2341 ± 501 (10) 369 ± 84 (6) 0.17 ± 0.03 (6) 
 
water paroxetine 1165 ± 167 (12) 240 ± 47 (12) 0.22 ± 0.03 (12) 
 
MAP saline 1821 ± 261 (6) 252 ± 44 (6) 0.14 ± 0.02 (6) 
 
MAP paroxetine 1105 ± 173 (12) 201 ± 32 (12) 0.22 ± 0.04 (12) 
week 3 water saline 2726 ± 470 (6) 306 ± 55 (6) 0.13 ± 0.03 (6) 
 
water paroxetine 1388 ± 167 (12)* 211 ± 24 (12) 0.19 ± 0.05 (12) 
 
MAP saline 2481 ± 534 (6) 306 ± 46 (6) 0.14 ± 0.04 (6) 
 
MAP paroxetine 2265 ± 453 (12) 223 ± 30 (12) 0.13 ± 0.02 (12) 
week 4 water saline 2410 ± 334 (6) 252 ± 47 (6) 0.10 ± 0.02 (5) 
 
water paroxetine 1218 ± 165 (12) 158 ± 23 (12) 0.14 ± 0.02 (12) 
 
MAP saline 2659 ± 619 (6) 252 ± 51 (6) 0.10 ± 0.01 (6) 
 
MAP paroxetine 1882 ± 360 (12) 159 ± 24 (12) 0.10 ± 0.01 (12) 
week 5 water saline 2701 ± 547 (6) 451 ± 194 (6) 0.17 ± 0.08 (6) 
 
water paroxetine 1108 ± 193 (12) 137 ± 15 (12) 0.14 ± 0.02 (12) 
 
MAP saline 2008 ± 279 (6) 208 ± 54 (6) 0.11 ± 0.01 (6) 
 
MAP paroxetine 1383 ± 266 (12) 202 ± 30 (12) 0.17 ± 0.02 (12) 
week 6 water saline 1901 ± 460 (6) 521 ± 226 (10) 0.32 ± 0.13 (6) 
 
water paroxetine 922 ± 173 (12)** 194 ± 33 (12) 0.27 ± 0.07 (12) 
 
MAP saline 1327 ± 430 (6) 254 ± 48 (6) 0.24 ± 0.05 (6) 
 MAP paroxetine 960 ± 225 (11) 181 ± 39 (11) 0.28 ± 0.08 (11) 
**P < 0.01 compares paroxetine/ water to saline/water group 891 
No significant differences were observed between paroxetine/MAP and water/MAP group 892 
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ABBREVIATIONS 893 
ANOVA – analysis of variance 894 
DA – dopamine 895 
DAT – dopamine transporter 896 
DD – dark-dark (constant darkness) 897 
FEO – food-entrainable oscillator 898 
HD – Huntington’s disease 899 
LD – light-dark 900 
MASCO – methamphetamine-sensitive circadian oscillator 901 
MAP – methamphetamine 902 
NA – noradrenaline 903 
NAc – nucleus accumbens 904 
SCN – suprachiasmatic nucleus 905 
SERT – serotonin transporter 906 
SSRI – selective serotonin reuptake inhibitor 907 
WT – wild type 908 
5-HT – serotonin 909 
